Myeloproliferative Disorders Drugs Market Size, Share & Trends Analysis Report By Indication (Ph- MPN (MF, PV, ET), Ph+ CML), By Major Markets, Competitive Landscape, And Segment Forecasts, 2018 - 2023
This report can be delivered to the clients within 72 Business hours
The global myeloproliferative disorder drugs market size is expected to be valued at USD 9.26 billion by 2023, as per a new report by Grand View Research, Inc., expanding at a CAGR of 3.4% during the forecast period. Availability of novel drugs, presence of a strong pipeline, rising incidence of myeloproliferative disorders due to changing lifestyles, growing geriatric population, and increasing public awareness are some of the primary growth stimulants for the market.Therapeutic development in second-line setting for Jakafi-intolerant patients is estimated to work in favor of the Ph- MPNs market.
Chronic myeloproliferative disorders are rare hematological malignances that involve abnormal accumulation of mature myeloid cells (red blood cells, granulocytes, and platelets) and their precursors (myelocytes, metamyelocytes, nucleated red blood cells, and megakaryocytes) in the peripheral blood and bone marrow. This class of disorder includes four main myeloproliferative diseases, which are further categorized by the presence of the Philadelphia chromosome.
There is a higher incidence of myeloproliferative disorders in North America and Western Europe as compared to East-Asian countries. Most patients are diagnosed with MPNs after 60 years of age, however, the diseases can occur in any age group.The U.S. will be the most prominent market for myeloproliferative disorders drugs owing to presence of a large target population.
Further key findings from the report suggest:
The global myeloproliferative disorder drugs market size is expected to be valued at USD 9.26 billion by 2023, as per a new report by Grand View Research, Inc., expanding at a CAGR of 3.4% during the forecast period. Availability of novel drugs, presence of a strong pipeline, rising incidence of myeloproliferative disorders due to changing lifestyles, growing geriatric population, and increasing public awareness are some of the primary growth stimulants for the market.Therapeutic development in second-line setting for Jakafi-intolerant patients is estimated to work in favor of the Ph- MPNs market.
Chronic myeloproliferative disorders are rare hematological malignances that involve abnormal accumulation of mature myeloid cells (red blood cells, granulocytes, and platelets) and their precursors (myelocytes, metamyelocytes, nucleated red blood cells, and megakaryocytes) in the peripheral blood and bone marrow. This class of disorder includes four main myeloproliferative diseases, which are further categorized by the presence of the Philadelphia chromosome.
There is a higher incidence of myeloproliferative disorders in North America and Western Europe as compared to East-Asian countries. Most patients are diagnosed with MPNs after 60 years of age, however, the diseases can occur in any age group.The U.S. will be the most prominent market for myeloproliferative disorders drugs owing to presence of a large target population.
Further key findings from the report suggest:
- The U.S. accounted for more than 45.0% of the market in 2017. Spiraling adoption of novel therapeutics and multiple product launches during the forecast period are anticipated to support the prominence of the market in global arena over the coming years
- Strong unmet needs are likely to shape the future of the market and encourage development of breakthrough first-in-class therapies. Opportunities remain in the Ph- MPNs setting where there exists an unmet need for a safer drug than Jakafi with higher cure rates and lesser allergic effects
- Some of the key market participants are Novartis, Bristol-Myers Squibb, Pfizer, Takeda, Incyte and Teva. Primary go-to strategies of prominent players include collaborations for development and regional expansion in emerging markets.
CHAPTER 1 RESEARCH METHODOLOGY
1.1. Information Procurement
1.2. Information or Data Analysis
1.2.1 Market Formulation & Validation
CHAPTER 2 EXECUTIVE SUMMARY
CHAPTER 3 DISEASE PRIMER AND EPIDEMIOLOGY
3.1. Disease Primer
3.2. Epidemiology
CHAPTER 4 GLOBAL MYELOPROLIFERATIVE DISORDERS DRUGS MARKET OVERVIEW
4.1 Market by Indication
4.2 Market Size and Forecast 2017 - 2023
4.3 Market Share Distribution, by Company 2017 - 2023
4.4 Market Dynamics and Brand Strategies
4.5 Patent Expiry Analysis
4.6 Myeloproliferative Disorders Market: Drivers and Restraints
4.6.1 Drivers
4.6.2 Challenges
4.7 M&A, Deal Landscape (2013 - 2018 YTD)
4.7.1 Mergers & Acquisitions
4.7.2 Deals Landscape
4.8 Reimbursement Scenario
4.9 Myeloproliferative Disorders Market: Sector SWOT
CHAPTER 5 MYELOPROLIFERATIVE DISORDERS MARKET: PIPELINE INTELLIGENCE
5.1. Pipeline Landscape
5.1.1 Leading Drugs in Development
5.1.2 Key R&D Trends
5.2 Pipeline Landscape
5.2.1 Late Stage Pipeline and Sales Forecast
5.2.2 Profiles of Disruptive Drugs
5.3 Global Pipeline Forecast
CHAPTER 6 COMPANY PROFILES
6.1 Novartis
6.1.1 Company Overview
6.1.2 Current Product Portfolio
6.1.3 Product Forecast Sales Through 2023
6.1.4 Strategic Initiatives
6.1.4.1 Key Company News Flow
6.1.5 Pipeline Analysis & Overview
6.1.6 SWOT
6.2 Bristol-Myers Squibb
6.2.1 Company Overview
6.2.2 Current Product Portfolio
6.2.3 Product Forecast Sales Through 2023
6.2.4 Strategic Initiatives
6.2.4.1 Key Company News Flow
6.2.5 Pipeline Analysis & Overview
6.2.6 SWOT
6.3 Pfizer
6.3.1 Company Overview
6.3.2 Current Product Portfolio
6.3.3 Product Forecast Sales Through 2023
6.3.4 Strategic Initiatives
6.3.4.1 Key Company News Flow
6.3.5 Pipeline Analysis & Overview
6.3.6 SWOT
6.4 Takeda
6.4.1 Company Overview
6.4.2 Current Product Portfolio
6.4.3 Product Forecast Sales Through 2023
6.4.4 Strategic Initiatives
6.4.4.1 Key Company News Flow
6.4.5 SWOT
6.5 Inctye
6.5.1 Company Overview
6.5.2 Current Product Portfolio
6.5.3 Product Forecast Sales Through 2023
6.5.4 Strategic Initiatives
6.5.4.1 Key Company News Flow
6.5.5 Pipeline Analysis & Overview
6.5.6 SWOT
6.6 Teva
6.6.1 Company Overview
6.6.2 Current Product Portfolio
6.6.3 Product Forecast Sales Through 2023
6.6.4 Strategic Initiatives
6.6.4.1 Key Company News Flow
6.6.5 SWOT
CHAPTER 7 MARKET OUTLOOK
7.1 What the Future Holds
7.2 The Winners and Losers
7.2.1 Winners
7.2.2 Losers
7.3 Emerging Companies & Technology Platforms
7.4 The Road Ahead
1.1. Information Procurement
1.2. Information or Data Analysis
1.2.1 Market Formulation & Validation
CHAPTER 2 EXECUTIVE SUMMARY
CHAPTER 3 DISEASE PRIMER AND EPIDEMIOLOGY
3.1. Disease Primer
3.2. Epidemiology
CHAPTER 4 GLOBAL MYELOPROLIFERATIVE DISORDERS DRUGS MARKET OVERVIEW
4.1 Market by Indication
4.2 Market Size and Forecast 2017 - 2023
4.3 Market Share Distribution, by Company 2017 - 2023
4.4 Market Dynamics and Brand Strategies
4.5 Patent Expiry Analysis
4.6 Myeloproliferative Disorders Market: Drivers and Restraints
4.6.1 Drivers
4.6.2 Challenges
4.7 M&A, Deal Landscape (2013 - 2018 YTD)
4.7.1 Mergers & Acquisitions
4.7.2 Deals Landscape
4.8 Reimbursement Scenario
4.9 Myeloproliferative Disorders Market: Sector SWOT
CHAPTER 5 MYELOPROLIFERATIVE DISORDERS MARKET: PIPELINE INTELLIGENCE
5.1. Pipeline Landscape
5.1.1 Leading Drugs in Development
5.1.2 Key R&D Trends
5.2 Pipeline Landscape
5.2.1 Late Stage Pipeline and Sales Forecast
5.2.2 Profiles of Disruptive Drugs
5.3 Global Pipeline Forecast
CHAPTER 6 COMPANY PROFILES
6.1 Novartis
6.1.1 Company Overview
6.1.2 Current Product Portfolio
6.1.3 Product Forecast Sales Through 2023
6.1.4 Strategic Initiatives
6.1.4.1 Key Company News Flow
6.1.5 Pipeline Analysis & Overview
6.1.6 SWOT
6.2 Bristol-Myers Squibb
6.2.1 Company Overview
6.2.2 Current Product Portfolio
6.2.3 Product Forecast Sales Through 2023
6.2.4 Strategic Initiatives
6.2.4.1 Key Company News Flow
6.2.5 Pipeline Analysis & Overview
6.2.6 SWOT
6.3 Pfizer
6.3.1 Company Overview
6.3.2 Current Product Portfolio
6.3.3 Product Forecast Sales Through 2023
6.3.4 Strategic Initiatives
6.3.4.1 Key Company News Flow
6.3.5 Pipeline Analysis & Overview
6.3.6 SWOT
6.4 Takeda
6.4.1 Company Overview
6.4.2 Current Product Portfolio
6.4.3 Product Forecast Sales Through 2023
6.4.4 Strategic Initiatives
6.4.4.1 Key Company News Flow
6.4.5 SWOT
6.5 Inctye
6.5.1 Company Overview
6.5.2 Current Product Portfolio
6.5.3 Product Forecast Sales Through 2023
6.5.4 Strategic Initiatives
6.5.4.1 Key Company News Flow
6.5.5 Pipeline Analysis & Overview
6.5.6 SWOT
6.6 Teva
6.6.1 Company Overview
6.6.2 Current Product Portfolio
6.6.3 Product Forecast Sales Through 2023
6.6.4 Strategic Initiatives
6.6.4.1 Key Company News Flow
6.6.5 SWOT
CHAPTER 7 MARKET OUTLOOK
7.1 What the Future Holds
7.2 The Winners and Losers
7.2.1 Winners
7.2.2 Losers
7.3 Emerging Companies & Technology Platforms
7.4 The Road Ahead
LIST OF TABLES
Table 1 Marketed Drugs for Myeloproliferative Disorders
Table 2 Sales Performance by Indication, 2017 -
Table 3 Ph+ CML Sales Performance by Country, in $ million, 2017 - 2023
Table 4 Ph- MPNs Sales Performance by Country, in $ million, 2017 - 2023
Table 5 U.S. Ph- MPNs Sales Performance, in $ million, 2017 - 2023
Table 6 U.K. Ph- MPNs Sales Performance, in $ million, 2017 - 2023
Table 7 Germany Ph- MPNs Sales Performance, in $ million, 2017 - 2023
Table 8 France Ph- MPNs Sales Performance, in $ million, 2017 - 2023
Table 9 Italy Ph- MPNs Sales Performance, in $ million, 2017 - 2023
Table 10 Spain Ph- MPNs Sales Performance, in $ million, 2017 - 2023
Table 11 Japan Ph- MPNs Sales Performance, in $ million, 2017 - 2023
Table 12 Patents Expiry for Current Myeloproliferative Disorders Drugs
Table 13 Annual price estimates of drugs approved for the treatment of CML, by Country
Table 14 R&D Pipeline Overview
Table 15 Late Stage Pipeline
Table 16 Asciminib (ABL001)
Table 17 NiCord
Table 18 Pacritinib
Table 19 Luspatercept (ACE-536)
Table 20 Pipeline Forecast
Table 21 Novartis Sales Forecast, 2017 - 2023
Table 22 Novartis Pipeline
Table 23 Bristol-Myers Squibb Sales Forecast, 2017 - 2023
Table 24 Bristol-Myers Squibb Pipeline
Table 25 Pfizer Sales Forecast, 2017 - 2023
Table 26 Pfizer Pipeline
Table 27 Takeda Sales Forecast, 2017 - 2023
Table 28 Incyte Sales Forecast, 2017 - 2023
Table 29 Incyte Pipeline
Table 30 Teva Sales Forecast, 2017 - 2023
Table 1 Marketed Drugs for Myeloproliferative Disorders
Table 2 Sales Performance by Indication, 2017 -
Table 3 Ph+ CML Sales Performance by Country, in $ million, 2017 - 2023
Table 4 Ph- MPNs Sales Performance by Country, in $ million, 2017 - 2023
Table 5 U.S. Ph- MPNs Sales Performance, in $ million, 2017 - 2023
Table 6 U.K. Ph- MPNs Sales Performance, in $ million, 2017 - 2023
Table 7 Germany Ph- MPNs Sales Performance, in $ million, 2017 - 2023
Table 8 France Ph- MPNs Sales Performance, in $ million, 2017 - 2023
Table 9 Italy Ph- MPNs Sales Performance, in $ million, 2017 - 2023
Table 10 Spain Ph- MPNs Sales Performance, in $ million, 2017 - 2023
Table 11 Japan Ph- MPNs Sales Performance, in $ million, 2017 - 2023
Table 12 Patents Expiry for Current Myeloproliferative Disorders Drugs
Table 13 Annual price estimates of drugs approved for the treatment of CML, by Country
Table 14 R&D Pipeline Overview
Table 15 Late Stage Pipeline
Table 16 Asciminib (ABL001)
Table 17 NiCord
Table 18 Pacritinib
Table 19 Luspatercept (ACE-536)
Table 20 Pipeline Forecast
Table 21 Novartis Sales Forecast, 2017 - 2023
Table 22 Novartis Pipeline
Table 23 Bristol-Myers Squibb Sales Forecast, 2017 - 2023
Table 24 Bristol-Myers Squibb Pipeline
Table 25 Pfizer Sales Forecast, 2017 - 2023
Table 26 Pfizer Pipeline
Table 27 Takeda Sales Forecast, 2017 - 2023
Table 28 Incyte Sales Forecast, 2017 - 2023
Table 29 Incyte Pipeline
Table 30 Teva Sales Forecast, 2017 - 2023
LIST OF FIGURES
Fig. 1 Market research process
Fig. 2 Information Procurement
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value chain based sizing & forecasting
Fig. 6 QFD modelling for market share assessment
Fig. 7 Myeloproliferative Disorders Market Share, by Treatment Type, 2017 &
Fig. 8 Regional Market Size, 2017 & 2023
Fig. 9 U.S. Myeloproliferative Disorders Drugs Market, $ million (2017 - 23)
Fig. 10 U.K. Myeloproliferative Disorders Drugs Market, $ million (2017 - 23)
Fig. 11 Germany Myeloproliferative Disorders Drugs Market, $ million (2017 - 23)
Fig. 12 France Myeloproliferative Disorders Drugs Market, $ million (2017 - 23)
Fig. 13 Italy Myeloproliferative Disorders Drugs Market, $ million (2017 - 23)
Fig. 14 Spain Myeloproliferative Disorders Drugs Market, $ million (2017 - 23)
Fig. 15 Japan Myeloproliferative Disorders Drugs Market, $ million (2017 - 23)
Fig. 16 Ph+ CML Market Shares Distribution, 2017 & 2023
Fig. 17 Ph- MPNs Market Shares Distribution, 2017 & 2023
Fig. 18 Myeloproliferative Disorders SWOT
Fig. 19 Myeloproliferative Disorders Pipeline Distribution
Fig. 20 Novartis Myeloproliferative Disorders Sales Forecast
Fig. 21 Novartis SWOT Analysis
Fig. 22 Bristol-Myers Squibb Myeloproliferative Disorders Sales Forecast
Fig. 23 Bristol-Myers Squibb SWOT Analysis
Fig. 24 Pfizer Myeloproliferative Disorders Sales Forecast
Fig. 25 Pfizer SWOT Analysis
Fig. 26 Takeda Myeloproliferative Disorders Sales Forecast
Fig. 27 Takeda SWOT Analysis
Fig. 28 Incyte Myeloproliferative Disorders Sales Forecast
Fig. 29 Incyte SWOT Analysis
Fig. 30 Teva Myeloproliferative Disorders Sales Forecast
Fig. 31 Teva SWOT Analysis
Fig. 1 Market research process
Fig. 2 Information Procurement
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value chain based sizing & forecasting
Fig. 6 QFD modelling for market share assessment
Fig. 7 Myeloproliferative Disorders Market Share, by Treatment Type, 2017 &
Fig. 8 Regional Market Size, 2017 & 2023
Fig. 9 U.S. Myeloproliferative Disorders Drugs Market, $ million (2017 - 23)
Fig. 10 U.K. Myeloproliferative Disorders Drugs Market, $ million (2017 - 23)
Fig. 11 Germany Myeloproliferative Disorders Drugs Market, $ million (2017 - 23)
Fig. 12 France Myeloproliferative Disorders Drugs Market, $ million (2017 - 23)
Fig. 13 Italy Myeloproliferative Disorders Drugs Market, $ million (2017 - 23)
Fig. 14 Spain Myeloproliferative Disorders Drugs Market, $ million (2017 - 23)
Fig. 15 Japan Myeloproliferative Disorders Drugs Market, $ million (2017 - 23)
Fig. 16 Ph+ CML Market Shares Distribution, 2017 & 2023
Fig. 17 Ph- MPNs Market Shares Distribution, 2017 & 2023
Fig. 18 Myeloproliferative Disorders SWOT
Fig. 19 Myeloproliferative Disorders Pipeline Distribution
Fig. 20 Novartis Myeloproliferative Disorders Sales Forecast
Fig. 21 Novartis SWOT Analysis
Fig. 22 Bristol-Myers Squibb Myeloproliferative Disorders Sales Forecast
Fig. 23 Bristol-Myers Squibb SWOT Analysis
Fig. 24 Pfizer Myeloproliferative Disorders Sales Forecast
Fig. 25 Pfizer SWOT Analysis
Fig. 26 Takeda Myeloproliferative Disorders Sales Forecast
Fig. 27 Takeda SWOT Analysis
Fig. 28 Incyte Myeloproliferative Disorders Sales Forecast
Fig. 29 Incyte SWOT Analysis
Fig. 30 Teva Myeloproliferative Disorders Sales Forecast
Fig. 31 Teva SWOT Analysis
